V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330010964 | 330005937 | 1.74 | 91 | Palliative (P) | 2016-02-12 | 2016-02-25 | Imatinib 400mg | 02 | N | 330024785 | CISPLATIN + DOCETAXEL |
| 330010965 | 330009236 | 1.87 | 78 | Adjuvant (A) | 2015-10-16 | 2015-12-18 | Cyclophosphamide High Dose | Y | null | 330024813 | CISPLATIN + DOXORUBICIN + ETOPOSIDE |
| 330010966 | 330009236 | 1.6 | 70 | Curative (C) | 2013-07-29 | 2013-07-29 | MELPHALAN | N | N | 330024813 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330010967 | 330005941 | 1.72 | 50 | Palliative (P) | 2018-04-02 | 2018-05-07 | ATG + Busulfan + Fludarabine | null | null | 330024829 | CARBOPLATIN + VINORELBINE |
| 330010968 | 330005943 | 1.55 | 58 | null | 2015-12-09 | 2015-12-23 | CLADRIBINE | N | N | 330024832 | LEAM |
| 330010969 | 330009238 | 0.86 | null | Neo-adjuvant (N) | 2013-11-23 | 2014-01-24 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | 330024844 | BENDAMUSTINE |
| 330010970 | 330005949 | null | 84.7 | Palliative (P) | 2015-02-15 | 2015-02-15 | MACE | N | N | 330024868 | CYTARABINE + MITOXANTRONE |
| 330010971 | 330005951 | null | 87.75 | Curative (C) | 2014-10-20 | 2014-11-15 | CARBOPLATIN + Cetuximab + FLUOROURACIL | null | null | 330024869 | CAP |
| 330010973 | 330005953 | 1.57 | null | Adjuvant (A) | 2016-10-30 | 2016-10-31 | PEMBROLIZUMAB | N | N | 330024880 | NILOTINIB |
| 330010974 | 330009243 | 1.78 | 78 | Palliative (P) | 2013-12-18 | 2013-12-21 | FLAG | Y | N | 330024882 | CVD |
| 330010975 | 330005956 | 1.58 | 81.2 | Palliative (P) | 2015-11-29 | 2015-12-18 | Alemtuzumab+Busulfan+CyclophosphMUD | 02 | N | 330024888 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330010976 | 330009247 | 1.73 | 15 | Palliative (P) | 2019-04-06 | 2019-05-27 | Carboplatin + Cetux + FU (Cycle 1) | N | N | 330024933 | FLA |
| 330010977 | 330005961 | 1.75 | 82 | Curative (C) | null | 2015-01-14 | EMA/CO | N | N | 330024941 | EMA/CO |
| 330010978 | 330005961 | 1.64 | 25.9 | null | 2013-09-15 | 2013-09-29 | ETOPOSIDE + IFOSFAMIDE + MTX | N | N | 330024941 | IMATINIB |
| 330010979 | 330005963 | 1.68 | 73.699 | Curative (C) | 2016-05-05 | 2016-05-07 | CYCLOPHOSPHAMIDE | 02 | N | 330024946 | CISPLATIN + DOXORUBICIN + ETOPOSIDE |
| 330010980 | 330005965 | 1.63 | null | Curative (C) | 2017-03-25 | 2017-07-17 | MITOTANE | 02 | null | 330024986 | FCR |
| 330010982 | 330005968 | 1.83 | 76.4 | Palliative (P) | 2017-11-06 | 2017-12-18 | Mitotane 4 - 4.5g | null | N | 330025006 | CARBOPLATIN + CETUXIMAB + FU |
| 330010983 | 330005968 | null | 109 | null | null | 2014-05-21 | DACTINOMYCIN + CYCLO + VINCRISTINE | null | N | 330025006 | PEMBROLIZUMAB |
| 330010984 | 330009253 | 1.77 | 65 | null | 2018-03-06 | 2018-03-06 | IPO | N | N | 330025020 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330010985 | 330009253 | null | null | Palliative (P) | 2017-10-11 | 2017-10-16 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | N | N | 330025020 | VINCRISTINE |
| 330010986 | 330005975 | 1.7 | 119 | Disease modification (D) | 2015-06-17 | 2015-08-21 | DHAP | N | null | 330025032 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330010987 | 330012014 | 1.78 | 86.4 | Adjuvant (A) | 2015-03-29 | 2015-05-03 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | null | 330025032 | CARBOPLATIN + VINORELBINE |
| 330010988 | 330005976 | 1.6 | 62.25 | Palliative (P) | 2014-07-30 | 2014-10-26 | R Chlorambucil | N | N | 330025041 | EMA/CO |
| 330010989 | 330009256 | 1.73 | 57.3 | Palliative (P) | 2015-06-25 | 2015-06-26 | IMMUNOGLOBULIN | 2 | N | 330025041 | AML18 TRIAL |
| 330010990 | 330009257 | 1.6 | 92 | Adjuvant (A) | 2018-11-05 | 2018-11-10 | AML Int Guide ADE 8+3+5 (2) | N | N | 330025052 | EMA/CO |
| 330010991 | 330009260 | 1.82 | 72.8 | Neo-adjuvant (N) | 2018-05-08 | 2018-05-29 | Cytarabine intrathecal | N | N | 330000079 | DOXORUBICIN + HD MTX |
| 330010992 | 330009260 | 1.69 | 74.6 | Curative (C) | 2016-04-23 | 2016-05-03 | Alemtuzumab + Cyclophos TBI Allo | 02 | N | 330000079 | IPILIMUMAB |
| 330010993 | 330005983 | 1.71 | 74 | Palliative (P) | null | 2017-04-22 | Capecitabine + Cisplatin | null | N | 330000343 | POMB |
| 330010994 | 330005986 | 1.75 | 43.5 | null | 2017-06-16 | 2017-06-16 | BEP 3 day | N | N | 330000507 | BEP |
| 330010995 | 330005988 | 1.69 | 87.6 | Curative (C) | 2017-05-27 | 2017-05-27 | Trastuzumab 21 day maintenance | 2 | N | 330000543 | IPILIMUMAB |
| 330010996 | 330009267 | null | 85 | Palliative (P) | 2015-01-28 | 2015-06-17 | IPO | N | N | 330000770 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 330010997 | 330005994 | 1.92 | 82.5 | Curative (C) | null | 2017-10-01 | CHOP R - 21 days | null | N | 330001004 | CARBOPLATIN + VINCRISTINE |
| 330010998 | 330009269 | 1.06 | null | Palliative (P) | 2017-05-13 | 2017-05-13 | Carboplatin + Thiotepa + Topotecan | 02 | N | 330001370 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330010999 | 330005998 | 1.66 | 71.5 | Palliative (P) | 2017-03-29 | 2017-03-29 | DHAP | N | N | 330002306 | DOXORUBICIN + HD MTX |
| 330011000 | 330011043 | 1.82 | 98.4 | Curative (C) | 2016-07-15 | 2016-07-15 | PEI | N | N | 330003920 | CVP R |
| 330011001 | 330011043 | 1.83 | 88.3 | Curative (C) | null | 2016-10-03 | CAELYX + CYCLOPHOSPHAMIDE + VINCRISTINE | N | N | 330003920 | DOXORUBICIN + HD MTX |
| 330011002 | 330006005 | null | 56.7 | Curative (C) | 2014-06-07 | 2014-06-08 | MAP + MIFAMURTIDE | N | null | 330004663 | CAP |
| 330011003 | 330006009 | 1.65 | 16.8 | Disease modification (D) | 2015-07-22 | 2015-08-17 | CISPLATIN + ETOPOSIDE + PACLITAXEL | N | N | 330004773 | MITOTANE |
| 330011004 | 330006012 | 1.71 | 54.8 | Curative (C) | 2017-08-08 | 2017-08-08 | FIGARO TRIAL | 2 | N | 330004965 | IVA |
| 330011005 | 330006014 | 1.83 | 74 | Palliative (P) | 2016-06-08 | 2016-06-26 | CHOP R - 21 days | N | N | 330004965 | CAPECITABINE + CISPLATIN |
| 330011006 | 330009276 | 1.76 | 30.4 | Palliative (P) | 2016-02-09 | 2016-02-09 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | 2 | N | 330005116 | BORTEZOMIB + RITUXIMAB |
| 330011007 | 330006016 | 1.64 | 75 | Palliative (P) | 2018-01-20 | 2018-08-12 | Carboplatin + Cetux + FU (>Cycle 2) | 02 | N | 330005236 | ALL MAINTENANCE |
| 330011008 | 330006017 | 1.7 | 22.2 | Disease modification (D) | 2019-02-25 | 2019-02-27 | Chlorambucil | N | N | 330005446 | IBRUTINIB |
| 330011009 | 330006020 | 0 | 53.2 | Curative (C) | 2018-08-13 | 2019-01-01 | EC | N | null | 330005775 | DACTINOMYCIN |
| 330011010 | 330009279 | 1.91 | 83.8 | Palliative (P) | 2018-07-06 | 2018-07-07 | Doxorubicin + Olaratumab | N | N | 330006301 | VIDE |
| 330011011 | 330009280 | 1.71 | 65.45 | Curative (C) | 2014-08-13 | 2015-07-27 | Trastuzumab Subcutaneous | null | N | 330006361 | DACARBAZINE + GEMCITABINE |
| 330011012 | 330011054 | 1.75 | 65.9 | Disease modification (D) | 2017-09-06 | 2018-05-19 | VIDE | Y | N | 330006669 | AML19 TRIAL |
| 330011013 | 330006026 | 1.55 | 0 | Palliative (P) | 2018-11-04 | 2018-11-10 | CISPLATIN + ETOPOSIDE + PACLITAXEL | 02 | null | 330006782 | MAP + MIFAMURTIDE |
| 330011014 | 330006028 | 1.59 | 60.9 | Palliative (P) | 2018-12-05 | 2018-12-05 | Erlotinib | N | N | 330006932 | AML17 TRIAL |
| 330011015 | 330011057 | null | null | Disease modification (D) | 2016-09-08 | 2016-09-11 | CISPLATIN + ETOPOSIDE + PACLITAXEL | Y | N | 330007236 | CARBOPLATIN + VINCRISTINE |